Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ipsen
Deal Size : $1,025.0 million
Deal Type : Acquisition
Merrimack Receives $225 Million Milestone Payment from Ipsen
Details : Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.
Product Name : Onivyde
Product Type : Other Small Molecule
Upfront Cash : $575.0 million
March 27, 2024
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ipsen
Deal Size : $1,025.0 million
Deal Type : Acquisition
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Ipsen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The press release indicates that the “the primary endpoint OS was not met in patients treated with Onivyde (irinotecan) versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed.
Product Name : Onivyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Ipsen
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Evaluating MM-310 in Patients With Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 10, 2017
Lead Product(s) : MM-151
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 27, 2016
Lead Product(s) : MM-151
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2015
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 02, 2015
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 26, 2015
Lead Product(s) : MM-121
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Elevation Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 12, 2015
Lead Product(s) : MM-121
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Elevation Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MM-302
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 11, 2014
Lead Product(s) : MM-302
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 24, 2013
Reset All
